Clinical Trial Update: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing endocrine therapy plus ribociclib versus chemotherapy for intermediate-risk HR+/HER2- early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• Kisqali (ribociclib) (ribociclib)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer Female | Phase 3 | Status: ACTIVE_NOT_RECRUITING